)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
VistaGen Therapeutics
VistaGen Therapeutics (VTGN) investor relations material
VistaGen Therapeutics AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 summary10 Sep, 2026
Opening remarks and agenda
Meeting held virtually to maximize stockholder participation and accessibility.
Agenda included three business items: election of directors, advisory vote on executive compensation, and ratification of the independent auditor.
Only questions related to agenda items were addressed during the meeting.
Board and executive committee updates
Introduction of board members, management team, and representatives from the independent auditing firm.
Attendance included key executives such as the CEO, CFO, and other senior officers.
Shareholder proposals
Election of four directors for one-year terms was proposed and put to a vote.
Advisory vote on executive compensation (Say on Pay) was proposed and seconded.
Ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending March 31, 2027, was proposed and seconded.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from VistaGen Therapeutics
- Net loss narrowed, cash runway into 2027, but going concern risk persists.VTGN
Q1 2027 - Board seeks approval for director elections, executive pay, and auditor ratification, emphasizing governance and ESG.VTGNProxy filing
- Shareholders will vote virtually on directors, executive pay, and auditor ratification in 2026.VTGNProxy filing
- Late-stage intranasal drugs show rapid, safe effects for anxiety, depression, and hot flashes.VTGNTD Cowen 45th Annual Health Care Conference
- Pivotal trials for novel neurocircuitry therapies advance, with key data expected next year.VTGNStifel 2024 Healthcare Conference
- Fasedienol missed primary endpoints in Phase 3 but showed promise in severe social anxiety subgroup.VTGNStudy update
- Net loss rose as R&D spending increased for late-stage trials; cash runway exceeds 12 months.VTGNQ2 2025
- Net loss rose to $10.7M as R&D spending increased; $108.4M in cash supports ongoing trials.VTGNQ1 2025
- Phase 3 SAD trials advance, net loss widens, R&D up, cash at $88.6M supports pipeline.VTGNQ3 2025
Next VistaGen Therapeutics earnings date
Q2 202712 Nov, 2026
VistaGen Therapeutics
Next VistaGen Therapeutics earnings date
Q2 202712 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
VistaGen Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders. The company's pipeline includes drug candidates designed to address mental health conditions such as anxiety, depression, and social anxiety disorder. VistaGen’s lead programs aim to provide rapid-acting treatments that target specific CNS pathways, offering potential alternatives to traditional therapies. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.